Cardiosense is a rapidly growing, medical AI company that is redefining how we detect, monitor, and manage heart disease. We’re developing a disease management platform built on novel wearable sensors and advanced machine learning algorithms that translate raw physiological signals into clinically actionable information to advance heart failure care both in-clinic and at home.

We’re excited to participate in the Pitch Competition because we believe our technology aligns perfectly with the HRX vision of the future of healthcare being virtual, informed by clinical needs, aided by sensors, powered by AI, and driven by innovators. We’re excited to showcase our technology to and network with many like-minded medical, technical, and business advocates at HRX.

We are building the world’s first ECG foundational model that applies AI to detect heart conditions just from an ECG traditionally only possible through echocardiography and invasive blood tests. HRX is a great opportunity for us to discuss our solution with thought leaders in cardiology and multiple stakeholders in a single platform. We are particularly excited to get feedback from different stakeholders at HRX on how we can improve our models and create value for patients.

Empallo is pioneering AI-guided value-based care for heart failure (HF) management, transforming patient care by enabling specialty HF treatment from home and extending quality life years. We’re thrilled to participate in the HRX Pitch Competition as it provides an exceptional platform to showcase our innovative approach and connect with leaders who share our vision for optimizing patient outcomes and reducing healthcare costs. We eagerly anticipate the opportunity to advance our mission and explore new possibilities through this event.

HrtEx is a digital healthcare company that provides software as a service and chronic disease management for large health care systems, self-insured companies, and primary care service companies. Our digital solution was conceived and developed by Stanford innovators through the renowned Stanford Biodesign Innovation program. Our team is led by experts in digital health technology and artificial intelligence and domain experts in hypertension, diabetes, heart failure, primary care, and chronic disease management.

We are excited to share our physician facing digital platform for Chronic Care Management with the HRX community and network.  We look forward to making new partnerships and collaborations as we hope our solution can help reduce the burden of cardiovascular diseases such as atrial fibrillation, ventricular tachycardia, and sudden cardiac death while improving patient outcomes as it improves the efficiency of care.

Hylomorph is a Healthtech pre-commercial, clinical-stage company, developing innovative drug-device combo products and digital solutions to prevent infection in patients with surgical implants. At Hylomorph, we commit to improve and save lives, by empowering doctors and embracing innovation.

Our first product, Vesta, is the next-generation envelope for cardiac rhythm management (CRM) devices. Vesta promotes functional tissue healing to stabilize the implant while providing sustained, localized delivery of antibiotics to prevent infection. Vesta is form-fitting to the CRM, cost-effective and flexible to tailor dosage and elution of novel drugs.

We are excited to participate in HRX as we fundraise for our final financing round towards FDA clearance, to engage investors and like-minded healthcare innovators who share our fulfilling purpose and pioneering passion for transforming patient care through groundbreaking medical technologies.

In a transformative time for AI in medicine, HRX’s focus on cardiovascular innovation aligns with the technology we are developing at iCardio.ai. We look forward and are excited about the opportunity to showcase our ground-breaking technology to HRX’s audience this September!

Kardiodiagnostix Inc. is a startup founded by Dr. Robert Chen (pediatric interventional cardiologist), Mr. Shameer Iqbal (AI expert), and Dr. Santokh Dhillon (pediatric electrophysiologist) with the goal of reducing the burden on health care systems while improving the quality and accessibility of care using innovative AI platforms. We are empowering healthcare through innovation.

We developed a deep-learning AI product for screening heart murmurs to reduce unnecessary referrals of innocent murmurs to pediatric specialists by 95% while improving detection of abnormal murmurs by 75%. Our product has an addressable market of US$1.5 billion annually for the care of children with murmurs in North America. The product will dramatically increase the effectiveness of primary care while drastically decreasing costs.

OurData gathered from 300 Canadian patients has been analyzed and confirms that our The platform will be deployed at the primary care level through insurance payers and government agencies. We have embarked on the regulatory path to Health Canada and FDA approval.

We are excited to pitch at HRX 2024. HRX is an excellent stage to share our innovation with a broader and diverse community of clinicians, software and AI experts, health care managers, venture capitalists and entrepreneurs, and regulatory agencies. We believe the HRX community will be as excited as we are to see this opportunity for artificial intelligence to play an increasingly vital role in the physical assessment of patients. We strongly believe, there are venture opportunities as the product heads to market in the next 18 months. We look forward to receiving commentary and feedback about this exciting product.

nucleusRx’s device-based virtual care platform empowers healthcare providers to remotely adjust at-home patient’s daily medication dispensing, and perform evidence-based remote titration or stepwise increase/decrease of doses to optimize medication therapy. Using nucleusRx platform healthcare providers can easily implement and optimize Guideline-Directed Medical Therapy or GDMT for at-home Heart Failure patients, stabilize patients at home, and reduce expensive hospital readmission.

We believe that HRX is a great platform for nucleusRx as it focuses on Heart Failure, a cardiac disease. We are excited at the opportunity to participate in the Pitch Competition because it further validates our mission by one of the most relevant groups of experts, and in addition gives us opportunities to network and learn from other industry participants.

Proton Intelligence  is developing the first ever wearable continuous potassium monitoring platform (like a Dexcom CGM, but for potassium) to help patients preserve their cardiorenal function and prevent deadly arrhythmias and crash dialysis. Our technology will optimize the prescription, dosing, and safety monitoring of critical therapies needed for GDMT for CHF, CKD, and resistant hypertension. We are excited to pitch to HRX, who are at the forefront of category-defining technologies for cardiology.

We’re excited to participate because we’ll get to meet others who are passionate about transforming heart health just like ourselves. Our technology has been years in development and the HRX pitch competition sounded like a great fit for us. We’re pre-commercialization and excited to spread the word about what we’ve developed. We’ve developed a noninvasive cardiac monitoring system that provides critical measurements regarding a patient’s heart health. Our team is led by Deborah Simpson, she has commercialized several medical products and sold 4 medical device companies. Deborah Simpson will be the one pitching at the event.

Third Coast Dynamics is developing precision diagnostics for the 11 million people in the United States who are at-risk for thoracic aortic disease and life-threatening outcomes, including aortic dissection and aneurysm rupture. Our cloud-based solution, TCDflow, uses deep learning to predict aortic hemodynamics (blood flow biomarkers) from widely available, low-cost standard anatomical imaging, such as CT and MR angiography. We envision creating a suite of precision diagnostics that incorporate advanced hemodynamic biomarkers, along with anatomical and clinical information, to identify patients at elevated risk for catastrophic aortic outcomes, so that these patients can undergo more frequent imaging surveillance and be referred for earlier consideration of elective aortic repair.

We are excited to share our technology with the HRX audience and look forward to learning about other new technologies in the cardiovascular disease space!